RCT for the Chinese Medicine in Treating Hypercholesterolemia
NCT ID: NCT06700408
Last Updated: 2024-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
70 participants
INTERVENTIONAL
2025-01-31
2027-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease Who Are Still Symptomatic After Optimal Medical Treatment
NCT07041359
A Clinical Trial of Chazhu Xiaozhi Decoction Against Non-alcoholic Fatty Liver Disease
NCT06442137
Cardiovascular-Protective Effects of Herbal Medicine Danshen-Gegen
NCT01033630
Chinese Medicine Therapy on Menopausal Symptoms
NCT00799734
Sacha Inchi Oil Supplementation in 3Hs
NCT04920825
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In recent years, there has been an increasing number of clinical studies of Traditional Chinese Medicine combinations or single herbs for hypercholesterolemia, and some drugs do have cholesterol-lowering effects, but the clinical evidence is not high due to bias or other deficiencies in trial design. Therefore, this clinical trial aim to evaluate the effectiveness of Dachaihu Decoction combined Erzhiwan with variation to the treatment of patients with clinical hypercholesterolemia, and tried to reduce its adverse effects on liver function through reasonable compatibility.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dachaihu Decoction combined Erzhiwan with variation granules
Chinese medicine granules
Dachaihu Decoction combined Erzhiwan with variation
Chinese medicine granules
Placebo granules
Placebo granules
Placebo granules
Placebo granules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dachaihu Decoction combined Erzhiwan with variation
Chinese medicine granules
Placebo granules
Placebo granules
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* LDL-C level of 4.1 mmol/L or above (no statin therapy during the screening period);
* Be able to maintain a more consistent lifestyle and eating habits throughout the study;
* Have a fixed residence and are not expected to move or travel for 8 weeks;
* Voluntarily sign the informed consent form.
Exclusion Criteria
* Alcohol or drug abuse within the last 3 months;
* Known liver function or renal dysfunction;
* History of severe cardiovascular and cerebrovascular diseases; or history of psychiatric illness;
* Participate in other interventional clinical trials within 3 months before the study, including drugs, supplements, medical devices, etc.;
* Known pregnant or lactating women, allergies or allergies to traditional Chinese medicine;
* Patients with known secondary hypercholesterolemia.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Lin Zhixiu
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhixiu Lin, Prof
Role: PRINCIPAL_INVESTIGATOR
Chinese University of Hong Kong
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hypercholesterolemia study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.